Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition

Q3 Medicine

Current Colorectal Cancer Reports Pub Date : 2017-09-18 DOI:10.1007/s11888-017-0388-z

M. Serzan, B. Weinberg, M. Salem

引用次数: 0

查看原文本刊更多论文

晚期癌症的二线治疗：EGFR与持续抑制VEGF

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Colorectal Cancer Reports ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of colorectal cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and emerging therapeutic approaches and the molecular basis of disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.